Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 58.87 USD 1.1% Market Closed
Market Cap: 119.4B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Intrinsic Value

The intrinsic value of one BMY stock under the Base Case scenario is 71 USD. Compared to the current market price of 58.87 USD, Bristol-Myers Squibb Co is Undervalued by 17%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BMY Intrinsic Value
71 USD
Undervaluation 17%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bristol-Myers Squibb Co

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BMY cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BMY?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Bristol-Myers Squibb Co

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Bristol-Myers Squibb Co

Provide an overview of the primary business activities
of Bristol-Myers Squibb Co.

What unique competitive advantages
does Bristol-Myers Squibb Co hold over its rivals?

What risks and challenges
does Bristol-Myers Squibb Co face in the near future?

Has there been any significant insider trading activity
in Bristol-Myers Squibb Co recently?

Summarize the latest earnings call
of Bristol-Myers Squibb Co.

What significant events have occurred
in Bristol-Myers Squibb Co over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bristol-Myers Squibb Co.

Provide P/S
for Bristol-Myers Squibb Co.

Provide P/E
for Bristol-Myers Squibb Co.

Provide P/OCF
for Bristol-Myers Squibb Co.

Provide P/FCFE
for Bristol-Myers Squibb Co.

Provide P/B
for Bristol-Myers Squibb Co.

Provide EV/S
for Bristol-Myers Squibb Co.

Provide EV/GP
for Bristol-Myers Squibb Co.

Provide EV/EBITDA
for Bristol-Myers Squibb Co.

Provide EV/EBIT
for Bristol-Myers Squibb Co.

Provide EV/OCF
for Bristol-Myers Squibb Co.

Provide EV/FCFF
for Bristol-Myers Squibb Co.

Provide EV/IC
for Bristol-Myers Squibb Co.

Show me price targets
for Bristol-Myers Squibb Co made by professional analysts.

What are the Revenue projections
for Bristol-Myers Squibb Co?

How accurate were the past Revenue estimates
for Bristol-Myers Squibb Co?

What are the Net Income projections
for Bristol-Myers Squibb Co?

How accurate were the past Net Income estimates
for Bristol-Myers Squibb Co?

What are the EPS projections
for Bristol-Myers Squibb Co?

How accurate were the past EPS estimates
for Bristol-Myers Squibb Co?

What are the EBIT projections
for Bristol-Myers Squibb Co?

How accurate were the past EBIT estimates
for Bristol-Myers Squibb Co?

Compare the revenue forecasts
for Bristol-Myers Squibb Co with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bristol-Myers Squibb Co and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bristol-Myers Squibb Co against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bristol-Myers Squibb Co compared to its peers.

Compare the P/E ratios
of Bristol-Myers Squibb Co against its peers.

Discuss the investment returns and shareholder value creation
comparing Bristol-Myers Squibb Co with its peers.

Analyze the financial leverage
of Bristol-Myers Squibb Co compared to its main competitors.

Show all profitability ratios
for Bristol-Myers Squibb Co.

Provide ROE
for Bristol-Myers Squibb Co.

Provide ROA
for Bristol-Myers Squibb Co.

Provide ROIC
for Bristol-Myers Squibb Co.

Provide ROCE
for Bristol-Myers Squibb Co.

Provide Gross Margin
for Bristol-Myers Squibb Co.

Provide Operating Margin
for Bristol-Myers Squibb Co.

Provide Net Margin
for Bristol-Myers Squibb Co.

Provide FCF Margin
for Bristol-Myers Squibb Co.

Show all solvency ratios
for Bristol-Myers Squibb Co.

Provide D/E Ratio
for Bristol-Myers Squibb Co.

Provide D/A Ratio
for Bristol-Myers Squibb Co.

Provide Interest Coverage Ratio
for Bristol-Myers Squibb Co.

Provide Altman Z-Score Ratio
for Bristol-Myers Squibb Co.

Provide Quick Ratio
for Bristol-Myers Squibb Co.

Provide Current Ratio
for Bristol-Myers Squibb Co.

Provide Cash Ratio
for Bristol-Myers Squibb Co.

What is the historical Revenue growth
over the last 5 years for Bristol-Myers Squibb Co?

What is the historical Net Income growth
over the last 5 years for Bristol-Myers Squibb Co?

What is the current Free Cash Flow
of Bristol-Myers Squibb Co?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bristol-Myers Squibb Co.

Business Breakdown

Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health a...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bristol-Myers Squibb Co

Current Assets 28.1B
Cash & Short-Term Investments 8.1B
Receivables 14.9B
Other Current Assets 5.1B
Non-Current Assets 65.6B
Long-Term Investments 2.4B
PP&E 8.3B
Intangibles 48.7B
Other Non-Current Assets 6.2B
Current Liabilities 22.6B
Accounts Payable 3.5B
Accrued Liabilities 13.3B
Short-Term Debt 205m
Other Current Liabilities 5.7B
Non-Current Liabilities 53.9B
Long-Term Debt 48.7B
Other Non-Current Liabilities 5.2B
Efficiency

Earnings Waterfall
Bristol-Myers Squibb Co

Revenue
47.4B USD
Cost of Revenue
-11.4B USD
Gross Profit
36B USD
Operating Expenses
-24.9B USD
Operating Income
11.1B USD
Other Expenses
-18.4B USD
Net Income
-7.3B USD

Free Cash Flow Analysis
Bristol-Myers Squibb Co

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, Bristol-Myers Squibb reported a 20% increase in growth portfolio revenues, now making up half of total sales. Key achievements included FDA approval for Cobinfi, a new treatment for schizophrenia, adding significant growth potential. For 2024, the company raised its revenue guidance to around a 5% increase, driven by higher-than-expected sales of Revlimid, expected at $5.5 billion. The overall operating margin target remains at 37%, supported by a $1.5 billion cost savings initiative. With robust cash flow, BMS aims to pay down $10 billion in debt by mid-2026 while continuing to invest in its pipeline and maintaining dividends.

What is Earnings Call?
Fundamental Scores

BMY Profitability Score
Profitability Due Diligence

Bristol-Myers Squibb Co's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Positive Operating Income
Positive 3-Year Average ROIC
55/100
Profitability
Score

Bristol-Myers Squibb Co's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

BMY Solvency Score
Solvency Due Diligence

Bristol-Myers Squibb Co's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average Altman Z-Score
Average Interest Coverage
37/100
Solvency
Score

Bristol-Myers Squibb Co's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BMY Price Targets Summary
Bristol-Myers Squibb Co

Wall Street analysts forecast BMY stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMY is 58.46 USD with a low forecast of 33.43 USD and a high forecast of 76.65 USD.

Lowest
Price Target
33.43 USD
43% Downside
Average
Price Target
58.46 USD
1% Downside
Highest
Price Target
76.65 USD
30% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BMY?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BMY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BMY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

BMY News

Other Videos

Profile

Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co

Country

United States of America

Industry

Pharmaceuticals

Market Cap

119.4B USD

Dividend Yield

4.08%

Description

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The firm offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Contact

NEW YORK
New York City
430 E 29th St Fl 14
+12125464000.0
www.bms.com

IPO

1929-07-05

Employees

32 200

Officers

CEO & Chairman
Dr. Christopher S. Boerner Ph.D.
Executive VP & CFO
Mr. David V. Elkins
Executive VP & General Counsel
Ms. Sandra Leung Esq.
Executive VP, Chief Medical Officer & Head of Development
Mr. Samit Hirawat M.D.
Executive VP and Chief Digital & Technology Officer
Mr. Greg Meyers
VP & Head of Investor Relations
Mr. Timothy Power
Show More
Chief Compliance & Ethics Officer
Ms. Kimberly M. Jablonski
Executive Vice President & Chief Human Resources Officer
Ms. Ahn Amanda Poole
Head of Medical Affairs
Dr. Joseph J. Eiden Jr.
Executive VP, Chief Commercialization Officer & Head of U.S. Oncology
Mr. Adam Lenkowsky
Show Less

See Also

Discover More
What is the Intrinsic Value of one BMY stock?

The intrinsic value of one BMY stock under the Base Case scenario is 71 USD.

Is BMY stock undervalued or overvalued?

Compared to the current market price of 58.87 USD, Bristol-Myers Squibb Co is Undervalued by 17%.

Back to Top